Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELAVL1 | Q15717 | 7/20 | 0.72 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 8/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 5/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | HTR7 | P34969 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19737482 | 0.88 | ELAVL1 (0.77) | ELAVL1HTR6POLBL3MBTL1MEN1 | |
| SCHEMBL19737490 | 0.85 | ELAVL1 (1.00) | ELAVL1HTR6L3MBTL1MEN1KMT2A | |
| Dimethylamine SCHEMBL21222569 | 0.83 | ELAVL1 (0.90) | ELAVL1HTR6L3MBTL1 | |
| SCHEMBL19737425 | 0.79 | ELAVL1 (0.83) | ELAVL1HTR6POLBL3MBTL1CTSG | |
| SCHEMBL19737426 | 0.79 | ELAVL1 (0.77) | ELAVL1BRD4HTR6L3MBTL1HTR2A | |
| SCHEMBL22130694 | 0.77 | ELAVL1 (0.79) | ELAVL1HTR6L3MBTL1ALDH1A1 | |
| SCHEMBL22130634 | 0.77 | ELAVL1 (0.83) | ELAVL1HTR6L3MBTL1CTSGCMA1 | |
| SCHEMBL21222486 | 0.77 | ELAVL1 (1.00) | ELAVL1HTR6L3MBTL1CTSGCMA1 | |
| SCHEMBL22130714 | 0.77 | ELAVL1 (0.83) | ELAVL1HTR6L3MBTL1MEN1KMT2A | |
| SCHEMBL22130693 | 0.76 | ELAVL1 (0.81) | ELAVL1HTR6L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | UNIVERSITA' DEGLI STUDI DI TRENTO (IT) | 2020-06-23 | — | — | US | disclosed |
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | UNIVERSITA' DEGLI STUDI DI TRENTO (IT) | 2020-06-23 | — | — | US | disclosed |
| US-20190241516-A1 | AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY | UNIVERSITA' DEGLI STUDI DI TRENTO (IT) | 2019-08-08 | — | — | US | disclosed |
| US-20190241516-A1 | AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY | UNIVERSITA' DEGLI STUDI DI TRENTO (IT) | 2019-08-08 | — | — | US | disclosed |
| WO-2017216732-A1 | AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241516-A1 | AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY | AZI2, TPMT, TYMS | ELAVL1 2765/4885BRD4 2031/4885HTR6 1922/4885 |
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | AZI2, TPMT, TYMS | ELAVL1 2765/4885BRD4 2031/4885HTR6 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.